Skip to main content
GPCR
NASDAQ Life Sciences

Structure Therapeutics Expands ATM Program to $400M, Reports Initial $58.5M in Share Sales

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$39.35
Mkt Cap
$2.893B
52W Low
$15.8
52W High
$94.9
52W Position info
149% above low
Off High info
59% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

GPCR has more than doubled off its 52-week low of $15.8.

Summary

Structure Therapeutics increased its At-The-Market (ATM) offering program to $400 million and reported initial sales of $58.5 million in ADSs.


Key Events · Financing and Capital Events · GPCR

  • ATM Program Expanded

    The company amended its sales agreement to increase the maximum aggregate offering amount under its At-The-Market (ATM) program to $400,000,000.

  • Initial Share Sales Reported

    Structure Therapeutics has already sold approximately $58.5 million (3,040,000 ADSs) through the ATM program, leaving a remaining capacity of $341,478,784.

  • Purpose of Proceeds

    Proceeds from the offering are designated for general corporate purposes, which may include funding research and development, clinical trials, and working capital.

  • Sales Agent Compensation

    Sales agents Leerink Partners LLC and Cantor Fitzgerald & Co. will receive a commission of up to 3.0% of the gross proceeds from any ADSs sold.


Analysis · GPCR · Life Sciences

Structure Therapeutics has significantly increased its At-The-Market (ATM) offering program to $400 million, up from the previously registered $250 million. This expansion provides the company with substantial flexibility to raise capital as needed. The filing also discloses that the company has already sold approximately $58.5 million in American Depositary Shares (ADSs) under the program. While this capital raise is dilutive to existing shareholders, it strengthens the company's already robust cash position, which was reported at $1.4 billion in its last 10-K, extending its operational runway through 2028. This move suggests the company is proactively securing additional funding for general corporate purposes, potentially including further clinical development or commercialization efforts, without the immediate pressure of a deep discount offering.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GPCR was trading at $39.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $15.80 to $94.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GPCR - Latest Insights

GPCR
Nov 11, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $20.95
Real-time Price: $19.55 info
Change: -$1.40 (-7%) info
Market Cap: $1.416B info
GPCR
Nov 09, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $19.55 info
Change: -$1.86 (-9%) info
Market Cap: $1.416B info
GPCR
Nov 09, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $19.55 info
Change: -$1.86 (-9%) info
Market Cap: $1.416B info
GPCR
Sep 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $36.78
Real-time Price: $19.55 info
Change: -$17.23 (-47%) info
Market Cap: $1.416B info
GPCR
Sep 08, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.60
Real-time Price: $19.55 info
Change: -$28.05 (-59%) info
Market Cap: $1.416B info